Use of hormones and risk of venous thromboembolism.

Autor:	de Barros VIPVL; Clínica Obstétrica Hospital das Clínicas Universidade de São Paulo São PauloSP Brasil Clínica Obstétrica, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brasil., de Oliveira ALML; Clínica Obstétrica Hospital das Clínicas Universidade de São Paulo São PauloSP Brasil Clínica Obstétrica, Hospital das Clínicas, Universidade de São Paulo, São Paulo, SP, Brasil., do Nascimento DJ; Departamento de Obstetrícia e Ginecologia Faculdade de Medicina Universidade Federal do Paraná CuritibaPR Brasil Departamento de Obstetrícia e Ginecologia, Faculdade de Medicina, Universidade Federal do Paraná, Curitiba, PR, Brasil., Zlotnik E; Hospital Israelita Albert Einstein São PauloSP Brasil Hospital Israelita Albert Einstein, São Paulo, SP, Brasil., Teruchkin MM; Hospital Moinhos de Vento Porto AlegreRS Brasil Hospital Moinhos de Vento, Porto Alegre, RS, Brasil., Marques MA; Universidade do Estado do Rio de Janeiro Rio de JaneiroRJ Brasil Universidade do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil.; Universidade Federal do Estado do Rio de Janeiro Rio de JaneiroRJ Brasil Universidade Federal do Estado do Rio de Janeiro, Rio de Janeiro, RJ, Brasil., Margarido PFR; Hospital Universitário Universidade de São Paulo São PauloSP Brasil Hospital Universitário, Universidade de São Paulo, São Paulo, SP, Brasil.
Jazyk:	angličtina
Zdroj:	Revista brasileira de ginecologia e obstetricia : revista da Federacao Brasileira das Sociedades de Ginecologia e Obstetricia [Rev Bras Ginecol Obstet] 2024 Apr 02; Vol. 46. Date of Electronic Publication: 2024 Apr 02 (Print Publication: 2024).
DOI:	10.61622/rbgo/2024FPS02
Abstrakt:	•The risk of venous thromboembolism (VTE) is not increased in women using long-acting reversible contraceptive methods (LARCs) with progestogens. •Oral contraceptives with levonorgestrel or norgestimate confer half the risk of VTE compared to oral contraceptives containing desogestrel, gestodene or drospirenone. •Progestogen-only pills do not confer an increased risk of VTE. •Women using transdermal contraceptive patches and combined oral contraceptives (COCs) are at an approximately eight times greater risk of VTE than non-users of hormonal contraceptives (HCs), corresponding to 9.7 events per 10,000 women/years. •Vaginal rings increase the risk of VTE by 6.5 times compared to not using HC, corresponding to 7.8 events per 10,000 women/years. •Several studies have demonstrated an increased risk of VTE in transgender individuals receiving hormone therapy (HT). •Hormone therapy during menopause increases the risk of VTE by approximately two times, and this risk is increased by obesity, thrombophilia, age over 60 years, surgery and immobilization. •The route of estrogen administration, the dosage and type of progestogen associated with estrogen may affect the risk of VTE in the climacteric. •Combined estrogen-progesterone therapy increases the risk of VTE compared to estrogen monotherapy. •Postmenopausal HT increases the risk of thrombosis at atypical sites. Competing Interests: Conflicts of interest: none to declare.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu